Lv42
440 积分 2022-09-08 加入
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
15天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
15天前
已完结
[Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2026 edition)]
20天前
已完结
Identifying prior evidence for new trials (REVEAL): guidance for clinical researchers
21天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
28天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
28天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
29天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
30天前
已完结
The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors
1个月前
已关闭
Epidermal Growth Factor Receptor Expression in Serous Ovarian Carcinoma: An Immunohistochemical Study With Galectin-3 and Cyclin D1 and Outcome
1个月前
已完结
皖公网安备34019202002308
